Features of the Course of Bronchiectatic Disease in Children

Bronchiectatic disease, also known as bronchiectasis, is a chronic, progressive respiratory condition that leads to irreversible bronchial wall dilation, persistent inflammation, and recurrent respiratory infections in children. Despite technological advances, its global burden remains significant, particularly in low- and middle-income countries, where early diagnosis and management are often lacking.
This descriptive-analytical study synthesizes data from recent international guidelines, pediatric pulmonology textbooks, and peer-reviewed articles to explore the epidemiology, etiology, clinical manifestations, diagnostic approaches, management strategies, and complications associated with bronchiectatic disease in children. Particular attention was given to differences between congenital and acquired causes, diagnostic imaging, and treatment modalities across regions.
The findings reveal that bronchiectasis most commonly develops between ages 3 and 6 and presents with chronic wet cough, sputum production, recurrent infections, and in advanced cases, physical signs such as digital clubbing and barrel chest. High-resolution computed tomography (HRCT) remains the gold standard for diagnosis, while pulmonary function tests and microbiological assessments aid in comprehensive care. Management requires a multidisciplinary approach combining antibiotics, bronchodilators, airway clearance techniques, nutritional support, and sometimes surgical intervention. Persistent challenges include limited healthcare access, delayed diagnosis, chronic bacterial colonization (notably Pseudomonas aeruginosa), and insufficient caregiver education.
Addressing bronchiectatic disease in children requires integrated clinical care, improved diagnostic infrastructure, and public health initiatives focusing on prevention and early intervention. Strengthening healthcare worker training, enhancing caregiver awareness, and supporting research on novel therapeutics and individualized treatment plans are crucial to reducing disease burden.
Coordinated efforts at clinical, public health, and research levels can significantly reduce the morbidity and mortality associated with pediatric bronchiectasis. By prioritizing prevention, early detection, and evidence-based interventions, it is possible to improve long-term outcomes and quality of life for affected children worldwide.